Relay Therapeutics, Inc. Increase (Decrease) in Prepaid Expense
Relay Therapeutics, Inc. (RLAY) reported Increase (Decrease) in Prepaid Expense of -$6.61 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2026-08-06
- Relay Therapeutics, Inc. increase (decrease) in prepaid expense for the quarter ending 2026-06-30 was $751.00K.
- Relay Therapeutics, Inc. increase (decrease) in prepaid expense for the quarter ending 2026-03-31 was -$7.36M, a 287.33% decline year-over-year.
- Relay Therapeutics, Inc. increase (decrease) in prepaid expense for the quarter ending 2025-12-31 was -$3.82M.
- Relay Therapeutics, Inc. increase (decrease) in prepaid expense for the quarter ending 2025-09-30 was $3.97M, a 58.97% decline year-over-year.
- Relay Therapeutics, Inc. increase (decrease) in prepaid expense for fiscal 2025 was -$1.61M, a 130.10% decline from fiscal 2024.
- Relay Therapeutics, Inc. increase (decrease) in prepaid expense for fiscal 2024 was $5.36M, a 15.23% increase from fiscal 2023.
- Relay Therapeutics, Inc. increase (decrease) in prepaid expense for fiscal 2023 was $4.65M, a 117.20% increase from fiscal 2022.
- Relay Therapeutics, Inc. increase (decrease) in prepaid expense for fiscal 2022 was $2.14M, a 20.18% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $751.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$6.61M 10-Q · filed 2026-08-06 | -$10.44M derived: sum of 3 quarters · filed 2026-08-06 | -$6.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$7.36M 10-Q · filed 2026-05-05 | -$11.19M derived: sum of 2 quarters · filed 2026-05-05 | -$7.22M derived: sum of 3 quarters · filed 2026-05-05 | -$12.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$3.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $144.00K derived: sum of 2 quarters · filed 2026-02-26 | -$5.54M derived: sum of 3 quarters · filed 2026-08-06 | -$1.61M 10-K · filed 2026-02-26 |
| 2025-09-30 | $3.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.72M derived: sum of 2 quarters · filed 2026-08-06 | $2.21M 10-Q · filed 2025-11-06 | $2.06M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$5.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.76M 10-Q · filed 2026-08-06 | -$1.90M derived: sum of 3 quarters · filed 2026-08-06 | $7.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.93M 10-Q · filed 2026-05-05 | $3.78M derived: sum of 2 quarters · filed 2026-05-05 | $13.45M derived: sum of 3 quarters · filed 2026-05-05 | $8.81M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$147.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.52M derived: sum of 2 quarters · filed 2026-02-26 | $4.88M derived: sum of 3 quarters · filed 2026-02-26 | $5.36M 10-K · filed 2026-02-26 |
| 2024-09-30 | $9.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $5.03M derived: sum of 2 quarters · filed 2025-11-06 | $5.50M 10-Q · filed 2025-11-06 | $4.55M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$4.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$4.16M 10-Q · filed 2025-08-07 | -$5.12M derived: sum of 3 quarters · filed 2026-02-26 | $3.16M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $475.00K 10-Q · filed 2025-05-05 | -$480.00K derived: sum of 2 quarters · filed 2026-02-26 | $7.79M derived: sum of 3 quarters · filed 2026-02-26 | $5.14M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$955.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.32M derived: sum of 2 quarters · filed 2026-02-26 | $4.66M derived: sum of 3 quarters · filed 2026-02-26 | $4.65M 10-K · filed 2026-02-26 |
| 2023-09-30 | $8.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $5.62M derived: sum of 2 quarters · filed 2024-11-06 | $5.60M 10-Q · filed 2024-11-06 | -$7.42M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | -$2.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$2.67M 10-Q · filed 2024-08-06 | -$15.69M derived: sum of 3 quarters · filed 2025-02-26 | -$53.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | -$16.00K 10-Q · filed 2024-05-02 | -$13.04M derived: sum of 2 quarters · filed 2025-02-26 | $2.60M derived: sum of 3 quarters · filed 2025-02-26 | $2.69M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | -$13.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $2.62M derived: sum of 2 quarters · filed 2025-02-26 | $2.71M derived: sum of 3 quarters · filed 2025-02-26 | $2.14M 10-K · filed 2025-02-26 |
| 2022-09-30 | $15.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $15.72M derived: sum of 2 quarters · filed 2023-11-02 | $15.16M 10-Q · filed 2023-11-02 | $10.69M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $88.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$478.00K 10-Q · filed 2023-08-08 | -$4.94M derived: sum of 3 quarters · filed 2024-02-22 | $7.17M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$566.00K 10-Q · filed 2023-05-04 | -$5.03M derived: sum of 2 quarters · filed 2024-02-22 | $7.08M derived: sum of 3 quarters · filed 2024-02-22 | $3.75M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$4.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $7.64M derived: sum of 2 quarters · filed 2024-02-22 | $4.31M derived: sum of 3 quarters · filed 2024-02-22 | $2.68M 10-K · filed 2024-02-22 |
| 2021-09-30 | $12.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $8.78M derived: sum of 2 quarters · filed 2022-11-03 | $7.15M 10-Q · filed 2022-11-03 | $8.15M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$3.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$4.96M 10-Q · filed 2022-08-04 | -$3.96M derived: sum of 3 quarters · filed 2023-02-23 | $762.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$1.63M 10-Q · filed 2022-05-05 | -$631.00K derived: sum of 2 quarters · filed 2023-02-23 | $4.09M derived: sum of 3 quarters · filed 2023-02-23 | $3.29M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $5.73M derived: sum of 2 quarters · filed 2023-02-23 | $4.93M derived: sum of 3 quarters · filed 2023-02-23 | $4.67M 10-K · filed 2023-02-23 |
| 2020-09-30 | $4.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $3.92M derived: sum of 2 quarters · filed 2021-11-10 | $3.66M 10-Q · filed 2021-11-10 | $4.68M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$800.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$1.06M 10-Q · filed 2021-08-12 | -$40.00K derived: sum of 3 quarters · filed 2022-02-24 | $765.00K derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$261.00K 10-Q · filed 2021-05-13 | $760.00K derived: sum of 2 quarters · filed 2022-02-24 | $1.56M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2019-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $1.83M derived: sum of 2 quarters · filed 2022-02-24 | $2.12M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $805.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.10M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $297.00K 10-Q · filed 2020-08-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |